Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 9,963 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MATCH Clear all
Completed Phase 1 Interventional

Mindfulness-Oriented Recovery Enhancement for Chronic Pain Patients Receiving Opioid Therapy

NCT01505101
View directory record Official record
Conditions
Chronic Pain, Opioid Abuse, Unspecified Use
Interventions
Mindfulness-Oriented Recovery Enhancement, Conventional Support Group (SG)
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 21, 2026, 10:56 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients

NCT01602367
View directory record Official record
Conditions
Hypertension
Interventions
BMS-823778, Placebo matching with BMS-823778
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
22
States / cities
Jonesboro, Arkansas • Los Angeles, California • Palm Springs, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 21, 2026, 10:56 AM EDT
Completed No phase listed Observational

Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)

NCT04358029
View directory record Official record
Conditions
COVID 19 Cardiac, COVID 16 Arrhythmia, COVID 19 Death
Interventions
Not listed
Lead sponsor
Vivek Reddy
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 21, 2026, 10:56 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Intravenous Neridronic Acid in CRPS

NCT03530345
View directory record Official record
Conditions
Complex Regional Pain Syndrome (CRPS)
Interventions
Neridronic acid 100 mg, Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Huntsville, Alabama • Mobile, Alabama • Peoria, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 21, 2026, 10:56 AM EDT
Completed Phase 1 Interventional

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

NCT04155645
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD8233 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Chula Vista, California • Glendale, California • La Mesa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 21, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants

NCT03281577
View directory record Official record
Conditions
Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions
TAK-954, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 21, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT07205081
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
Interventions
ATTO-3712, Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
9
States / cities
Encinitas, California • Fountain Valley, California • Huntington Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 10:56 AM EDT
Completed Phase 4 Interventional Results available

A Study to Compare Efficacy and Safety of Trifarotene Cream When Used With an Oral Antibiotic for the Treatment of Severe Acne Vulgaris (AV)

NCT04451330
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene cream, Doxycycline hyclate, Trifarotene Vehicle, Doxycycline Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Rogers, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 21, 2026, 10:56 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

NCT07144527
View directory record Official record
Conditions
Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
Interventions
NMN and TMG (Euexia), Nicotinamide Mononucleotide (NMN), Placebo
Dietary Supplement
Lead sponsor
Scott Silveira
Other
Eligibility
60 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 21, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

SH-DS01 on Fecal Metagenomic Stability

NCT04598295
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DS-01
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 21, 2026, 10:56 AM EDT
Recruiting Phase 4 Interventional

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

NCT05282277
View directory record Official record
Conditions
Depression, Psychosis, Anhedonia
Interventions
Transdermal Estradiol, Micronized Progesterone, Matching Placebo Patch, Raclopride C11
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 21, 2026, 10:56 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

NCT04164901
View directory record Official record
Conditions
Grade 2 Glioma, Residual Glioma, Recurrent Glioma
Interventions
Vorasidenib, Matching Placebo
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
12 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
40
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 21, 2026, 10:56 AM EDT
Completed Phase 3 Interventional

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

NCT00754988
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Metformin, Placebo (matching sitagliptin), Placebo (matching taspoglutide), Sitagliptin, Taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
64
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tallassee, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 21, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment

NCT01675661
View directory record Official record
Conditions
Cannabis Dependence
Interventions
N-Acetylcysteine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 50 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 21, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

NCT02152761
View directory record Official record
Conditions
Muscle Wasting (Atrophy) After Hip Fracture Surgery
Interventions
bimagrumab, placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Phoenix, Arizona • El Cajon, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Oct 21, 2026, 10:56 AM EDT
Not listed No phase listed Observational

BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

NCT04264702
View directory record Official record
Conditions
Colorectal Cancer, Colon Cancer
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Carlos, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 21, 2026, 10:56 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

NCT02367313
View directory record Official record
Conditions
Asthma
Interventions
Vapendavir, Placebo
Drug
Lead sponsor
Biota Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Bakersfield, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 21, 2026, 10:56 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Communication Strategies to Increase HPV Vaccinations

NCT06784960
View directory record Official record
Conditions
Papilloma Viral Infection, Vaccine Hesitancy, Communication
Interventions
HPV Message 1, HPV Message 2, HPV Message 3, Control Message, Provider Strong-Recommendation Toolkit
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
9,002 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 21, 2026, 10:56 AM EDT
Completed No phase listed Observational

MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research

NCT02313623
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate Fusion Biopsy
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 21, 2026, 10:56 AM EDT
Completed Phase 4 Interventional Results available

Bupropion for Smoking Cessation During Pregnancy

NCT01390246
View directory record Official record
Conditions
Pregnancy Related, Tobacco Use Disorder
Interventions
Bupropion SR, Smoking Cessation Counseling, Placebo
Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 21, 2026, 10:56 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease

NCT01731990
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Canakinumab (ACZ885), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 21, 2026, 10:56 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

NCT03024996
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Atezolizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
45
States / cities
Scottsdale, Arizona • Duarte, California • Lancaster, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 21, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

NCT00567190
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Pertuzumab, Placebo, Trastuzumab, Docetaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
159
States / cities
Scottsdale, Arizona • Jonesboro, Arkansas • Alhambra, California + 120 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 21, 2026, 10:56 AM EDT
Completed Phase 2 Interventional

A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures

NCT06769659
View directory record Official record
Conditions
Epilepsy, Generalized, Epilepsy, Absence
Interventions
NPT 2042, Placebo
Drug · Other
Lead sponsor
NeuroPro Therapeutics, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 10:56 AM EDT